The MFDS’ verification advisory group composed of domestic experts presented an opinion that there was no reason to exclude the administration of AstraZeneca's COVID-19 vaccine to the elderly. In addition, it was evaluated that the inoculation was performed twice at the standard dose, and the inoculation interval was appropriate for 4 to 12 weeks.

The verification advisory group held a meeting on the 31st of last month and made such a decision on AstraZeneca's COVID-19 vaccine.

Many experts who participated in the verification advisory group said that ▲the clinical trial plan was designed to confirm the efficacy and safety in subjects over 18 years old, ▲the prevention effect was confi